Li Zhang

651 Dong Feng East Road
Guangzhou, 510060, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 143 publications

DNA hypomethylation identifying clinical benefit subgroup of small-cell lung cancer: multi-omics analysis of a phase II trial with durvalumab plus olaparib as maintenance therapy.

DNA hypomethylation identifying clinical benefit subgroup of small-cell lung cancer: multi-omics analysis of a phase II trial with durvalumab plus olaparib as maintenance therapy.

Journal: Journal for immunotherapy of cancer

Published: August 05, 2026

Correction: Lymphocyte activating gene 3 protein expression in nasopharyngeal carcinoma is correlated with programmed cell death-1 and programmed cell death ligand-1, tumor-infiltrating lymphocytes.

Correction: Lymphocyte activating gene 3 protein expression in nasopharyngeal carcinoma is correlated with programmed cell death-1 and programmed cell death ligand-1, tumor-infiltrating lymphocytes.

Journal: Cancer cell international

Published: June 17, 2026

A phase 2 study of encorafenib in combination with binimetinib for Chinese participants with BRAFV600E mutated metastatic non-small cell lung cancer: Results from the OCEAN II study.

A phase 2 study of encorafenib in combination with binimetinib for Chinese participants with BRAFV600E mutated metastatic non-small cell lung cancer: Results from the OCEAN II study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: June 17, 2026

Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial.

Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial.

Journal: The Lancet. Oncology

Published: March 20, 2026

Targeting internalization, resistance, and response: Insights from ICARUS-LUNG01.

Targeting internalization, resistance, and response: Insights from ICARUS-LUNG01.

Journal: Cancer cell

Published: February 27, 2026

Correction: Tertiary lymphoid structures gene signature predicts response to immunotherapy plus chemotherapy in advanced non-small cell lung cancer.

Correction: Tertiary lymphoid structures gene signature predicts response to immunotherapy plus chemotherapy in advanced non-small cell lung cancer.

Journal: Cancer immunology, immunotherapy : CII

Published: October 28, 2025

FAK activation drives non-genetic adaptive survival of ALK-rearranged lung cancer under tyrosine kinase inhibitor treatment.

FAK activation drives non-genetic adaptive survival of ALK-rearranged lung cancer under tyrosine kinase inhibitor treatment.

Journal: Journal of genetics and genomics = Yi chuan xue bao

Published: October 26, 2025

Diverse genomic and transcriptomic heterogeneity in EGFR-mutant lung adenocarcinoma between exon 19 del and exon 21 L858R.

Diverse genomic and transcriptomic heterogeneity in EGFR-mutant lung adenocarcinoma between exon 19 del and exon 21 L858R.

Journal: Cell communication and signaling : CCS

Published: October 14, 2025

Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials.

Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: October 07, 2025

Discovery of XNW5004 as a novel EZH2 inhibitor that enhances anti-tumor immunity and synergizes with PD-1 blockade immunotherapy in lung adenocarcinoma.

Discovery of XNW5004 as a novel EZH2 inhibitor that enhances anti-tumor immunity and synergizes with PD-1 blockade immunotherapy in lung adenocarcinoma.

Journal: Journal of translational medicine

Published: September 23, 2025

Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China.

Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China.

Journal: Lancet (London, England)

Published: September 08, 2025

JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1G2032R resistance mutation in NSCLC: The first-in-human phase 1 trial.

JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1G2032R resistance mutation in NSCLC: The first-in-human phase 1 trial.

Journal: Cancer cell

Published: August 01, 2025

Showing 1-12 of 143

Last Updated: 09/26/2026